NCCN 2^nd Annual Congress: Hematologic Malignancies – Myelodysplastic Syndromes: Who Would Benefit From Immunosuppressive Therapy?

Download Podcast

Listen to MP3

Podcast Evaluation

A presentation from the NCCN 2^nd Annual Congress: Hematologic Malignancies™ held September 14-15, 2007, in New York, New York

Presenter

Maria R. Baer, MD
The University of Maryland Greenebaum Cancer Center
Baltimore, Maryland

Faculty Disclosure Statement

Dr. Baer has disclosed that she has no financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in her presentation or who may financially support the educational activity. 

Dr. Baer has indicated that her presentation will not include discussion of investigational or unlabeled uses of a product.

Program Overview

Treatment of hematologic malignancies is increasingly complex.  Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of new advances.  In addition, targeted therapies and oral treatments bring new benefits to patients. This program will focus on the role of immunosuppressive therapy in the management of myelodysplastic syndromes (MDS).

Educational Objectives

Following this activity, participants should be able to:

• Identify the available therapeutic options for MDS
• Describe patients with MDS who may benefit from immunosuppressive therapy

Intended Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation.  Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety.  You must be connected to the Internet in order to review and complete the evaluation form.  A statement of credit will be electronically generated once you complete the evaluation form.  To receive credit, this activity must be completed no later than November 1, 2008.  There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 0.25 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date:  November 1, 2007
Expiration date:  November 1, 2008